Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 79 - 86 |
| Number of pages | 8 |
| Journal | Drug Safety |
| Volume | 38 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2015 |
Cite this
}
Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. / Clothier, Hazel; Hosking, Laine; Crawford, Nigel; Russell, Melissa; Easton, Mee Lee; Quinn, Julie-Ann; Buttery, James Peter.
In: Drug Safety, Vol. 38, No. 1, 2015, p. 79 - 86.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system
AU - Clothier, Hazel
AU - Hosking, Laine
AU - Crawford, Nigel
AU - Russell, Melissa
AU - Easton, Mee Lee
AU - Quinn, Julie-Ann
AU - Buttery, James Peter
PY - 2015
Y1 - 2015
N2 - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.
AB - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.
UR - http://link.springer.com/article/10.1007%2Fs40264-014-0248-6
U2 - 10.1007/s40264-014-0248-6
DO - 10.1007/s40264-014-0248-6
M3 - Article
VL - 38
SP - 79
EP - 86
JO - Drug Safety
JF - Drug Safety
SN - 0114-5916
IS - 1
ER -